Tuesday - May 6, 2025

LOGIN  |  REGISTER
Cue Biopharma
Recursion

Nuvation Bio to Participate in the Jefferies Virtual Healthcare Conference

May 26, 2021 | Last Trade: US$2.38 0.08 -3.25

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that David Hung, M.D., founder and chief executive officer of Nuvation Bio, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021, at 9:00 a.m. ET.

(PRNewsfoto/Nuvation Bio, Inc.)

The fireside chat will be webcast live and can be accessed under "Events & Presentations" in the "Investors" section of the Company's website at www.nuvationbio.com. The webcast will be archived for a period of 30 days following the conclusion of the live event.

About Nuvation Bio

Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco. For more information, please visit www.nuvationbio.com.

Nuvation Bio Investor Contact:
ir@nuvationbio.com

Nuvation Bio Media Contact:
Argot Partners
Leo Vartorella
leo@argotpartners.com  

C4 Therapeutics

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page